Pivotal phase III trial of MAT 9001 for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia

Next Previous
Trial Profile

Pivotal phase III trial of MAT 9001 for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia

Planning
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2014

At a glance

  • Drugs MAT 9001 (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Matinas BioPharma

    • Most Recent Events

    • 29 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top